Cloning - Archive

On Matters of Life and Death, Where Are We Now?

Taking Stock: Where Are We Now?

Taking stock of where one is at the beginning of a new project or a new year is a good idea. Where we are in the entire realm of bioethics is beyond the scope of a mere e-newsletter, but what follows are some landmarks discernible in January 2016 . . .
On Matters of Life and Death
Physician-Assisted Suicide

On Sunday, 24 January, John Jay Hooker, Tennessee lawyer, politician, and activist, died. Mr. Hooker had most recently championed “death with dignity” –physician-assisted suicide — in a proposed bill and in the courts. By the time of his death, neither the legislature nor the courts had provided him the decision he had recently pursued.

The “Death with Dignity” bill was sponsored in the Tennessee legislature by Rep. Craig Fitzhugh, D-Ripley. Quoted in The Tennessean, Mr. Fitzhugh honored his friend, Mr. Hooker, with these words: “I found his love for our great state to be enormous, and unceasing. Until his last breath, he was committed to helping others, fighting for what he believed to be right, and being a voice for the voiceless.” There seems no lack of dignity in Mr. Hooker’s death.

We are HERE: Mr. Hooker died while his case was pending before the Tennessee Court of Appeals, and that case awaits another plaintiff —

Three-Parent Embryos

These were approved in the UK in (February) 2015 —

We are HERE: In the U.S., the matter is under consideration by the FDA, and we await their decision.


How it works:
“Everything You Need to Know About CRISPR, the New Tool that Edits DNA”
(Gizmodo 6 May 2015)

“Scientists Capture Crispr’s Gene-Cutting in Action”
(Wired 14 Jan 2016)

We are HERE:

Predictions for 2016: “CRISPR will make 2016 the year of gene-edited organisms” (New Scientist, 15 Dec 2015)

Who controls it? “This week, the fierce battle over who invented it officially kicked off, with hundreds of millions of dollars on the line.” (Washington Post, 13 Jan 2016)

Ban proposed: “We must not engineer the genes we pass on to our descendants.” (Center for Genetics and Society)

The Tennessee Center for Bioethics & Culture will do our part to keep you informed.
[30 Jan 2016, D. Joy Riley, M.D., M.A., Executive Director, email]

About Inheritable Genetic Modification
Inheritable genetic modification (IGM, also called germline engineering) means changing the genes passed on to future generations. The genetic changes would be made in eggs, sperm or early embryos; modified genes would appear not only in the person who developed from that gamete or embryo, but also in all succeeding generations. IGM has not been tried in humans. It would be by far the most consequential type of genetic modification as it would open the door to irreversibly altering the human species.
Proposals for inheritable genetic modification in humans combine techniques involving in vitro fertilization (IVF), gene transfer, stem cells and research cloning.

Center for Genetics and Society releases open letter and report calling for prohibitions on human germline engineering
[Press Release]Nov 29, 2015 Scholars, health practitioners, scientists, public interest advocates, and others have signed a CGS-organized open letter calling for strengthened prohibitions against heritable human genetic modification —

Open Letter Calls for Prohibition on Reproductive Human Germline Modification
by Center for Genetics and Society Experiments aimed at creating genetically modified humans are unneeded from a medical view, extremely risky to any resulting children, and profoundly dangerous from a social perspective. Now is the crucial moment for taking a clear public stand —
The New Eugenics

One of the most profound and layered questions raised by recent genetic advances is this: Do we as a species still want babies born with genetic disabilities?

Science is scoring great successes in combating the 7,000 genetic ailments that can strike our children — and that sounds great. Yet it’s difficult to draw a line where we stop “improving” our species. Many disability activists argue that we’re moving toward a new eugenics, and I’m afraid that they could be right.

The first step toward upgrading our descendants will come in the treatment of disabilities because the benefits are so obvious. And so I sat down here in London with an expert on disability and genetics, someone whose struggle with the issue is not just scholarly but also personal — to me as well as him.

It all began when my British great-uncle, Sir Geoffrey Shakespeare, had a son, William. That’s right: he became Sir William Shakespeare. (We in the family have always claimed to be related to the Bard as descendants of his cousin Humphrey Shakespeare; it’s a coincidence that this column is written in iambic pentameter.)

William was born with a genetic mutation that results in achondroplasia, a kind of dwarfism. William became a fine doctor (his short stature gave him a rapport with child patients), and his eldest son, my cousin Tom, was also born with achondroplasia. And Tom in turn has a daughter with achondroplasia as well.

Tom Shakespeare inherited the title and is formally Sir Thomas (which mortifies him), as well as a leading scholar on genetics and disability. As we sat down at a London coffee shop to talk about these issues, Tom attracted attention because he’s not only the shortest person around but also the most self-confident, charming and funky, with earrings and tremendous presence.

“Society sees disability as the worst thing that can happen,” Tom says. “It’s one thing that can happen, but not the worst.” All in all, he says, he’s had more opportunities than if he had been born without a disability but into a poor family.

Tom says many disabled people feel threatened by genetic advances and are hurt by cheerful talk about engineering a world without people like them. “That’s very difficult for disabled people,” Tom says. “To hear people discuss a world in which you don’t exist can be very hurtful.”

“People ask me all the time, `Wouldn’t you rather have been not short?’ But that’s almost like saying, `Wouldn’t you rather have not been born?’ ”

Yet Tom notes that his own views have also evolved, and he struggled with the question of whether he would have another child with his same condition. Every father wants a child like himself, yet also a child with every advantage. In the end, he says, he will not have more children, partly because of the risk of disability.

If that’s a knotty question, so is the broader one we face as a species. I disagree with those disability leaders who oppose strong efforts to combat genetic diseases. But I think they’re right to ring alarm bells. The problem is that it may eventually become possible not just to cull embryos associated with dwarfism, but also to screen out baldness, pug noses or homosexuality, or even to choose the embryo most likely to get into Yale.

My guess is that germ-line gene therapy will arrive a bit further down the road, initially to fix “bad genes” that cause disease, and then moving on to enhance intelligence and performance. I’m afraid we may be slipping, without any conscious decision or even awareness of the implications, toward a future in which we will hugely accelerate our own evolution, in which our descendants quickly diverge from all that has been human for 200,000 years.

Bill McKibben, in his cautionary new book about genetic science, “Enough,” articulates the dangers as he recalls a childhood friend, Kathy, who died of cystic fibrosis:

“Why not at least let the germ-line engineers go to work on the Kathys of the world? The harm is not to the patient but to the world in which she lives. As even proponents acknowledge, the line between repair and enhancement is too murky to be meaningful. Soon you’re headed toward a world where Kathy’s lungs work fine, but where her goodness, her kindness, don’t mean what they did. Where someone’s souping up her brains or regulating her temper, not just clearing up her mucus.”
[Nicholas D. Kristof, New York Times, July 4th, 2003, ]

Genetics and Society website contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of biotechnology and public policy issues. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.